Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EED | O75530 | 1/20 | 0.49 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.49 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.49 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.49 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.48 |
| ▸ | PDE4A | P27815 | 2/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.48 |
| ▸ | STS | P08842 | 4/20 | 0.47 |
| ▸ | TOP2A | P11388 | 1/20 | 0.47 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.45 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.45 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.45 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.45 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.45 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.45 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15864843 | 0.89 | TOP2A (0.50) | PDE4BPDE4DPDE4APDE4CSTS | |
| SCHEMBL3166432 | 0.86 | PDE4B (0.51) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL3283282 | 0.86 | PDE4B (0.53) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL15864679 | 0.85 | EZH2 (0.39) | EZH2 | |
| SCHEMBL15864933 | 0.84 | EZH2 (0.39) | EZH2 | |
| SCHEMBL15864924 | 0.83 | ATM (0.46) | EZH2 | |
| SCHEMBL13280087 | 0.83 | ALDH1A1 (0.51) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL17208275 | 0.81 | CACNB4 (0.46) | EZH2PDE4BCACNB4CACNA1ACACNA1G | |
| SCHEMBL15864917 | 0.81 | CACNB4 (0.46) | EZH2PDE4BCACNB4CACNA1ACACNA1G | |
| SCHEMBL15864915 | 0.81 | CACNB4 (0.46) | EZH2PDE4BCACNB4CACNA1ACACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382234-B2 | Enhancer of Zeste Homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382234-B2 | Enhancer of Zeste Homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382234-B2 | Enhancer of Zeste Homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150307480-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC | 2015-10-29 | — | — | US | disclosed |
| US-20150307480-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC | 2015-10-29 | — | — | US | disclosed |
| US-20150307480-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC | 2015-10-29 | — | — | US | disclosed |
| EP-2931707-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | Glaxosmithkline LLC (US) | 2015-10-21 | — | — | EP | disclosed |
| WO-2014107277-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-07-10 | — | — | WO | disclosed |
| WO-2014107277-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307480-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, BMI1, EZH1 | EED 5/4885RBBP4 190/4885SUZ12 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.